PRESS RELEASE published on 02/25/2026 at 07:00, 2 months 10 days ago Sandoz delivers strong full-year results; guidance for 2026 reflects an expected acceleration in growth Sandoz reports strong full-year results for 2025 with net sales growth and core EBITDA margin expansion. The guidance for 2026 anticipates further growth in net sales and core EBITDA margin Net Sales Growth Full-year Results Sandoz Financial Guidance 2026 Core EBITDA Margin Expansion
PRESS RELEASE published on 02/25/2026 at 07:00, 2 months 10 days ago Leclanché Appoints Jens Emrich as Chief Financial Officer Leclanché SA appoints Jens Emrich as Chief Financial Officer, bringing 25 years of finance leadership experience. Emrich to join on 1st March 2026 Chief Financial Officer Appointment Leclanché SA Finance Leadership Jens Emrich
PRESS RELEASE published on 02/25/2026 at 07:00, 2 months 10 days ago Leclanché nomme Jens Emrich au poste de directeur financier Leclanché nomme Jens Emrich au poste de directeur financier. Jens Emrich apporte plus de 25 ans d'expérience internationale dans les secteurs industriels et énergétiques. Nomination chez Leclanché SA Nomination Leclanché Directeur Financier Expérience Jens Emrich
PRESS RELEASE published on 02/25/2026 at 07:00, 2 months 10 days ago Nordex Group reports solid Q4/2025 results, enabling the company to meet all financial and operational targets for 2025 and to exceed its previously communicated mid‑term EBITDA margin target Nordex Group reports solid Q4/2025 results, meeting and exceeding financial and operational targets. New mid-term EBITDA margin target set at 10-12%. Sales expected to be EUR 8.2-9.0 billion for 2026 Financial Targets EBITDA Margin Nordex Group Mid-term Target Q4/2025 Results
REGULATED PRESS RELEASE published on 02/25/2026 at 07:00, 2 months 10 days ago Résultats 2025. Une performance solide dans un contexte perturbé. Marge opérationnelle : 19.5% - Marge nette : 14.1 % - Dividende par action : 1.05€ Interparfums affiche des marges élevées en 2025 malgré un contexte perturbé. Dividende par action de 1,05 € et investissements en RSE. Perspectives 1er trimestre 2026 impactées par la parité euro dollar Interparfums Dividende RSE Perspectives Marges Élevées
REGULATED PRESS RELEASE published on 02/25/2026 at 07:00, 2 months 10 days ago 2025 results. Solid performance in an unstable environment. Operating margin: 19.5% - Net margin: 14.1% - Dividend per share: €1.05 Interparfums reports solid performance in 2025 despite external challenges, maintaining high margins. Financial results show stable operating and net margins Financial Performance Interparfums Operating Margin Net Margin 2025 Results
REGULATED PRESS RELEASE published on 02/25/2026 at 06:59, 2 months 10 days ago OPmobility - 2025 Annual Results and Governance OPmobility reports strong 2025 full-year results with operating margin up +11.4% to €490 million, EBITDAe) up +7.7% to €1,001 million, and net debt reduced by -€167 million. Félicie Burelle confirmed as CEO, diversification strategy confirmed in North America and Asia Operating Margin Diversification Strategy OPmobility Félicie Burelle 2025 Full-year Results
REGULATED PRESS RELEASE published on 02/25/2026 at 06:59, 2 months 10 days ago OPmobility - Résultats annuels 2025 et Gouvernance
PRESS RELEASE published on 02/25/2026 at 06:45, 2 months 10 days ago #FutureFresenius: REJUVENATE in action – Delivering accelerated performance for long-term value creation; 2025 yet another year of strong delivery Fresenius SE & Co. KGaA reports strong FY/25 results with 7% organic revenue growth and 12% Core EPS growth. Improved EBIT margin and increased dividend proposal. #FutureFresenius strategy aims for sustainable growth Financial Results Organic Revenue Growth Fresenius Core EPS #FutureFresenius
PRESS RELEASE published on 02/25/2026 at 06:30, 2 months 10 days ago Formycon announces positive clinical data for Keytruda® biosimilar candidate FYB206 (pembrolizumab) Formycon announces positive clinical data for Keytruda biosimilar candidate FYB206 (pembrolizumab), confirming pharmacokinetic equivalence with Keytruda Clinical Data Biosimilar Formycon Keytruda Pembrolizumab
Published on 05/07/2026 at 18:30, 2 hours 29 minutes ago Silver Storm Announces Mobilization of Underground Mine Development Contractors at La Parrilla
Published on 05/07/2026 at 16:35, 4 hours 24 minutes ago Caledonia Mining Corporation Plc New Corporate Video
Published on 05/07/2026 at 15:15, 5 hours 44 minutes ago ACCESS Newswire Launches ACCESS Insights & Analytics, AI-Powered Press Release Scoring Platform
Published on 05/07/2026 at 14:35, 6 hours 24 minutes ago Worksport (NASDAQ: WKSP) Announces Q1 2026 Earnings Call Date and Launch of Investor Townhall Series
Published on 05/07/2026 at 14:30, 6 hours 29 minutes ago Rio Grande Resources Announces Results of First Annual General Meeting and Re-Appointments
Published on 05/07/2026 at 20:42, 16 minutes ago RHÖN-KLINIKUM AG reports stable development in the first quarter of 2026
Published on 05/07/2026 at 18:46, 2 hours 13 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 05/07/2026 at 18:35, 2 hours 24 minutes ago Seminole Hard Rock Casino Named Official Miami World Cup 2026™ Host City Supporter
Published on 05/07/2026 at 18:00, 2 hours 59 minutes ago Correction d’un communiqué du 05.05.2026 21:46 CET/CEST - E-PANGO: Composition du capital au 30 avril 2026
Published on 05/07/2026 at 19:15, 1 hour 44 minutes ago 2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 1 hour 44 minutes ago Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Published on 05/07/2026 at 19:06, 1 hour 53 minutes ago Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 19:06, 1 hour 53 minutes ago Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Published on 05/07/2026 at 19:00, 1 hour 59 minutes ago ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL